Immix Biopharma (IMMX) Total Non-Current Liabilities (2020 - 2021)
Immix Biopharma's Total Non-Current Liabilities came in at -$23.21 million for Q4 2021, compared with $4.7 million a year earlier.
Powered by 
Analysis
Immix Biopharma (IMMX) Total Non-Current Liabilities (2020 - 2021) Analysis & Trends
- Going back by year, Total Non-Current Liabilities was $4.7 million in FY2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 106.45 Bn |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | 80.25 Bn |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | -967.00 Mn |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 81.11 Bn |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | 36.04 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 5.92 Bn |
| 10 | Immix Biopharma | 753.99 Mn | 753.99 Mn | - | - |
API Access
Immix Biopharma Total Non-Current Liabilities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=IMMX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "total-non-current-liabilities", "ticker": "IMMX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=IMMX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();